Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
暂无分享,去创建一个
G. Ceresoli | A. Maconi | F. Grosso | P. Zucali | M. Perrino | M. Pless | P. Froesch | C. Appenzeller | M. Früh | M. Schneider | Y. Metaxas | M. Mark | S. Schmid | E. Eboulet | C. Biaggi-Rudolf | R. von Moos | C. Waibel | D. Rauch
[1] R. Stahel,et al. A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial , 2019, Annals of Oncology.
[2] S. Lantuejoul,et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. , 2019, The Lancet. Oncology.
[3] N. Pavlakis,et al. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] I. Ray-Coquard,et al. Phase III trial of lurbinectedin versus PLD or topotecan in platinum-resistant ovarian cancer patients: Results of CORAIL trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] S. Barni,et al. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. , 2018, Respiratory medicine.
[6] S. Novello,et al. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. , 2018, The Lancet. Oncology.
[7] K. Nackaerts,et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. , 2017, The Lancet. Oncology.
[8] P. Allavena,et al. Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models , 2017, British Journal of Cancer.
[9] R. Stahel,et al. Relapse pattern and second-line treatment following multimodality treatment for malignant pleural mesothelioma. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[10] G. Ceresoli,et al. Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma. , 2015, Cancer treatment reviews.
[11] Bingshu E. Chen,et al. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome. , 2015, European journal of cancer.
[12] J. V. van Meerbeeck,et al. Second line therapy in malignant pleural mesothelioma: A systematic review. , 2015, Lung cancer.
[13] J. Lafitte,et al. Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. , 2015, The Lancet. Oncology.
[14] G. Ceresoli,et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. , 2014, Lung cancer.
[15] I. Ray-Coquard,et al. Lurbinectedin (PM01183), an active compound in platinum-resistant/refractory ovarian cancer (PRROC) patients: Results of a two-stage, controlled phase II study. , 2014 .
[16] G. Ceresoli,et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. , 2012, Lung cancer.
[17] R. Stahel,et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] A. Tod,et al. Living with mesothelioma. A literature review. , 2009, European journal of cancer care.
[19] R. Ramlau,et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Cindy B. Yeoh,et al. Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[21] A. Musk,et al. Malignant mesothelioma , 2005, The Lancet.
[22] M. Byrne,et al. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] J. V. van Meerbeeck,et al. The role of gemcitabine in the treatment of malignant mesothelioma. , 2002, Seminars in oncology.
[24] J. Herndon,et al. A design alternative for two-stage, phase II, multicenter cancer clinical trials. , 1998, Controlled clinical trials.
[25] P. V. Van Schil,et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.